5.Chalmers, Z.R., et al. “Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.” Genome Med 9.1(2017): p. 34. 6.Rizvi, H., et al. “Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 a...
这是TMB首次获得FDA批准成为指导患者治疗选择的生物标志物。 近日,Nature Cancer发表了观点文章“The status of tumor mutational burden and immunotherapy”,美国约翰霍普金斯大学医学院Valsamo Anagnostou、意大利都灵大学Alberto Bardelli、美国...
[1].Gross L. Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line[J]. Cancer Research, 1943, 3(5): 326-333. [2].Babbitt B P, Allen P M, Matsueda G R, et al. Binding of immunogenic peptides to Ia histocompatibility molecules.[J]. ...
Cancer Cell. 2021; 39(2): 154-173. 2. 中国抗癌协会肿瘤标志专业委员会遗传性肿瘤标志物协作组,中国抗癌协会肿瘤病理专业委员会分子病理协作组. 肿瘤突变负荷检测及临床应用中国专家共识(2020 年版). 中国癌症防治杂志 2020年10月,第12卷,第5期. 3. Genetic basis for clinical response to CTLA-4 ...
5、TMB阈值该如何定呢? 先看以往数据 看Checkmate 026: Phase 3 NSCLC 再看IMvigor 211 (urothelial cancer phase 3) 再看CheckMate 227: Phase 3 NSCLC Co-primary Endpoint: PFS With Nivolumab + Ipilimumab vs Chemotherapy in Patients With High TMB (≥10 mut/Mb) PFS in Patients With High TMB (≥...
Dedong Cao, Huilin Xu, Ximing Xu, Tao Guo & Wei Ge. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients, OncoImmunology(2019) 作者| 细胞中心白泽 来源| 上海细胞治疗工程技术研究中心...
参考文献: Goodman AM, et al., Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers,Mol Cancer Ther. 2017 Nov;16(11):2598-2608.
了解更多关于生物标记物的的药物研发、市场与法规等领域的关键问题,推荐关注第二届现代临床分子诊断研讨会,会议邀请了40+大咖嘉宾演讲,其中专注于癌症早期精准诊断生物标记物研发肖桂山教授,将在大会上作题为“Clinical utility of biomarkers in diagnosis and prognosis of cancer”的演讲,敬请期待!
lung cancer: an exploratory analysis of CheckMate 026 [abstract CTO82]. Cancer Res. 2017;77(13) (suppl):ct082. doi:10.1158/1538-7445.AM2017-CT082 6. Carbone DP, Reck M, Paz-Ares L, et al; CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non–small-cell lu...
过去以PCR毛细管电泳法作为MSI检测的金标准, 基于美国国家癌症研究所(National Cancer Institute, NCI)推荐的5~7个经典微卫星位点, 对比肿瘤细胞与正常细胞的检测结果, 以确定肿瘤细胞的MSI状态。 近年来, NGS panel开始用于MSI检测, 使用计算工具同时研究基因组上的大量微卫星序列成为可能。且多数NGS-MSI算法采用正常...